Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15328211 | 0.86 | PIK3C3 (0.35) | ALDH1A1CYP2D6MEN1KMT2APOLB | |
| SCHEMBL15328234 | 0.83 | DDR1 (0.42) | ALDH1A1CYP2D6CYP2C9POLBMAPT | |
| SCHEMBL15733353 | 0.82 | NAPEPLD (0.40) | ALDH1A1CYP2C9POLBSMN1; SMN2TSHR | |
| SCHEMBL15328555 | 0.80 | ALDH1A1 (0.37) | ALDH1A1CYP2D6CYP2C9POLBMAPT | |
| SCHEMBL2134391 | 0.80 | RAB9A (0.43) | ALDH1A1CYP2C9SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL2130364 | 0.79 | RAB9A (0.42) | ALDH1A1CYP2C9SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL15328261 | 0.78 | KMT2A (0.47) | MEN1KMT2ASMN1; SMN2EGFRCDK2 | |
| SCHEMBL15328723 | 0.78 | KMT2A (0.42) | ALDH1A1CYP2C9MEN1KMT2APOLB | |
| SCHEMBL15328404 | 0.76 | SRC (0.49) | ALDH1A1MAPT | |
| SCHEMBL2128118 | 0.75 | RAB9A (0.40) | ALDH1A1CYP2C9POLBSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | claimed |
| EP-2844645-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-03-11 | — | — | EP | claimed |
| WO-2013156155-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-10-24 | — | — | WO | claimed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | claimed |
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| EP-2844645-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-03-11 | — | — | EP | disclosed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| WO-2013156155-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | KCNJ2, KCNQ2, KCNQ1 | ALDH1A1 3041/4885CYP2D6 704/4885CYP2C9 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.